No effects of ozonated autohemotherapy on inflammation response in hemodialyzed patients.
BACKGROUND
Ozone as a strong oxidant may induce an inflammatory response.


OBJECTIVE
The hypothesis was verified as to whether ozonated autohemotherapy using an ozone dose in therapeutic range changes the plasma concentration of C-reactive protein and interleukin-6, markers of inflammation.


METHODS
In a controlled, single-blind, cross-over study, 12 chronically hemodialyzed patients with peripheral arterial disease were exposed to nine sessions of autohemotherapy with blood exposure to oxygen as a control followed by nine sessions of ozonated autohemotherapy with an ozone concentration of 50 microg/ml.


RESULTS
There was no statistical difference between C-reactive protein levels at baseline (1.53 +/- 1.01 mg/l), after nine sessions of control autohemotherapy (1.48 +/- 0.96 mg/l), and after nine sessions of ozonated autohemotherapy (1.55 +/- 0.84 mg/l). There was also no statistical difference between the interleukin-6 serum concentration at baseline (438 +/- 118 pg/ml), after nine sessions of control autohemotherapy (444 +/- 120 pg/ml), and after nine sessions of ozonated autohemotherapy (466 +/- 152 pg/ml).


CONCLUSIONS
The results of this study suggest that ozonated autohemotherapy using an ozone concentration of 50 microg/ml does not induce an inflammatory response.
Tylicki
Leszek
L
Department of Nephrology, Transplantology and Internal Medicine, Medical University of Gdansk, ul. Debinki 7, 80-211 Gdansk, Poland. leszek.tylicki@amg.gda.pl
Biedunkiewicz
Bogdan
B
Rachon
Dominik
D
Nieweglowski
Tomasz
T
Hak
Lukasz
L
Chamienia
Andrzej
A
Debska-Slizien
Alicja
A
Aleksandrowicz
Ewa
E
Mysliwska
Jolanta
J
Rutkowski
Boleslaw
B
D002097:C-Reactive Protein / Q000378:metabolism; D018592:Cross-Over Studies; D006801:Humans; D018836:Inflammation Mediators / Q000378:metabolism*; D015850:Interleukin-6 / Q000097:blood; D010126:Ozone / Q000009:adverse effects / Q000627:therapeutic use*; D016491:Peripheral Vascular Diseases / Q000097:blood / Q000188:drug therapy; D006435:Renal Dialysis; D012449:Safety; D016037:Single-Blind Method
D018836:Inflammation Mediators; D015850:Interleukin-6; D010126:Ozone; D002097:C-Reactive Protein